These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21931028)

  • 41. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.
    Stokes ME; Muehlenbein CE; Marciniak MD; Faries DE; Motabar S; Gillespie TW; Lipscomb J; Knopf KB; Buesching DP
    J Manag Care Pharm; 2009 Oct; 15(8):669-82. PubMed ID: 19803556
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treating low-risk febrile neutropenia: Jenny's story.
    Phillips R; Skinner R; Chisholm JC
    Arch Dis Child; 2007 Jan; 92(1):7-8. PubMed ID: 17185442
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients.
    Park JR; Coughlin J; Hawkins D; Friedman DL; Burns JL; Pendergrass T
    Med Pediatr Oncol; 2003 Feb; 40(2):93-8. PubMed ID: 12461792
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Once daily, oral, outpatient quinolone monotherapy for low-risk cancer patients with fever and neutropenia: a pilot study of 40 patients based on validated risk-prediction rules.
    Rolston KV; Manzullo EF; Elting LS; Frisbee-Hume SE; McMahon L; Theriault RL; Patel S; Benjamin RS
    Cancer; 2006 Jun; 106(11):2489-94. PubMed ID: 16628654
    [TBL] [Abstract][Full Text] [Related]  

  • 45. First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study.
    Brack E; Bodmer N; Simon A; Leibundgut K; Kühne T; Niggli FK; Ammann RA
    Pediatr Blood Cancer; 2012 Sep; 59(3):423-30. PubMed ID: 22271702
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta-analysis.
    Teuffel O; Ethier MC; Alibhai SMH; Beyene J; Sung L
    Ann Oncol; 2011 Nov; 22(11):2358-2365. PubMed ID: 21363878
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [An organizational and economic approach in France to the ambulatory treatment of febrile neutropenia].
    Turlure P; Durand-Zaleski I
    Presse Med; 2004 Mar; 33(5):338-42. PubMed ID: 15041886
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antibiotic treatment of febrile episodes in neutropenic cancer patients. Clinical and economic considerations.
    de Lalla F
    Drugs; 1997 May; 53(5):789-804. PubMed ID: 9129866
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The outpatient management of febrile neutropenia in cancer patients.
    Freifeld AG; Pizzo PA
    Oncology (Williston Park); 1996 Apr; 10(4):599-606, 611-2; discussion 615-6. PubMed ID: 8723296
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Which children with fever and neutropenia can be safely treated as outpatients?
    Mullen CA
    Br J Haematol; 2001 Mar; 112(4):832-7. PubMed ID: 11298578
    [No Abstract]   [Full Text] [Related]  

  • 51. Outpatient treatment of febrile neutropenic patients with cancer.
    Rubenstein EB; Rolston KV
    Eur J Cancer; 1995; 31A(1):2-4. PubMed ID: 7695973
    [No Abstract]   [Full Text] [Related]  

  • 52. Controversies in new antibiotic therapy for ambulatory patients.
    Sundararajan V; Rubenstein EB; Rolston KV; Elting LS
    Support Care Cancer; 1997 Sep; 5(5):358-64. PubMed ID: 9322346
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.
    Innes H; Lim SL; Hall A; Chan SY; Bhalla N; Marshall E
    Support Care Cancer; 2008 May; 16(5):485-91. PubMed ID: 17899215
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin.
    Chamilos G; Bamias A; Efstathiou E; Zorzou PM; Kastritis E; Kostis E; Papadimitriou C; Dimopoulos MA
    Cancer; 2005 Jun; 103(12):2629-35. PubMed ID: 15856427
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Single-agent, broad-spectrum fluoroquinolones for the outpatient treatment of low-risk febrile neutropenia.
    Cooper MR; Durand CR; Beaulac MT; Steinberg M
    Ann Pharmacother; 2011 Sep; 45(9):1094-102. PubMed ID: 21862714
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of febrile neutropenia is expensive: prevention is the answer.
    Klastersky JA; Paesmans M
    Onkologie; 2011; 34(5):226-8. PubMed ID: 21577026
    [No Abstract]   [Full Text] [Related]  

  • 57. Outpatient management of febrile neutropenia: time to revise the present treatment strategy.
    Carstensen M; Sørensen JB
    J Support Oncol; 2008; 6(5):199-208. PubMed ID: 18551855
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inpatient versus outpatient management of neutropenic fever in gynecologic oncology patients: is risk stratification useful?
    Gunderson CC; Farrell R; Dinh BC; Thomas ED; Vesely SK; Lauer JK; Kao L; Chopra S; McMeekin DS; Moore KN
    Gynecol Oncol; 2013 Sep; 130(3):411-5. PubMed ID: 23791827
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fever and neutropenia--how to use a new treatment strategy.
    Finberg RW; Talcott JA
    N Engl J Med; 1999 Jul; 341(5):362-3. PubMed ID: 10423472
    [No Abstract]   [Full Text] [Related]  

  • 60. Outpatient antibiotic therapy in febrile neutropenic patients undergoing high-dose chemotherapy and autologous bone marrow support.
    Rubenstein EB; Rolston K; Elting L
    J Clin Oncol; 1994 Nov; 12(11):2516-7. PubMed ID: 7964970
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.